HCPCS Level II code A9180 identifies topical treatments for pediculosis (lice infestation) intended for administration by the patient or a caregiver. This code is used when medication is supplied for home use rather than applied by a clinician, and it matters nationally because pediculosis is a common condition across pediatric and adult populations that often requires outpatient, community, or home-based management. Accurate coding affects coverage determination, pharmacy dispensing, and claims processing for these commonly used topical agents.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the code, expected sites of service, typical billing considerations, and the types of benchmarks and policy issues that influence coverage and claims adjudication for self-administered topical lice treatments. The publication outlines common modifiers and payer patterns where available, notes areas where inputs were not provided, and situates the code within broader outpatient and pharmacy-managed care workflows. This summary is intended to help billing managers, revenue integrity teams, and policy analysts understand the functional role of A9180 in claims and benefit design at a national level.